

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1707	(514/300,546/113).CCLS.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/08/23 11:30
L2	278957	l1 and CRF receptor antagonist	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/08/23 11:31
L3	13	l1 and (CRF adj receptor adj antagonist)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	OFF	2007/08/23 11:37

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 MAY 01 New CAS web site launched
NEWS 3 MAY 08 CA/CAPLUS Indian patent publication number format defined
NEWS 4 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 5 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 6 MAY 21 TOXCENTER enhanced with BIOSIS reload
NEWS 7 MAY 21 CA/CAPLUS enhanced with additional kind codes for German patents
NEWS 8 MAY 22 CA/CAPLUS enhanced with IPC reclassification in Japanese patents
NEWS 9 JUN 27 CA/CAPLUS enhanced with pre-1967 CAS Registry Numbers
NEWS 10 JUN 29 STN Viewer now available
NEWS 11 JUN 29 STN Express, Version 8.2, now available
NEWS 12 JUL 02 LEMBASE coverage updated
NEWS 13 JUL 02 LEMEDLINE coverage updated
NEWS 14 JUL 02 SCISEARCH enhanced with complete author names
NEWS 15 JUL 02 CHEMCATS accession numbers revised
NEWS 16 JUL 02 CA/CAPLUS enhanced with utility model patents from China
NEWS 17 JUL 16 CAPLUS enhanced with French and German abstracts
NEWS 18 JUL 18 CA/CAPLUS patent coverage enhanced
NEWS 19 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 20 JUL 30 USGENE now available on STN
NEWS 21 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 22 AUG 06 BEILSTEIN updated with new compounds
NEWS 23 AUG 06 FSTA enhanced with new thesaurus edition
NEWS 24 AUG 13 CA/CAPLUS enhanced with additional kind codes for granted patents
NEWS 25 AUG 20 CA/CAPLUS enhanced with CAS indexing in pre-1907 records

NEWS EXPRESS 29 JUNE 2007: CURRENT WINDOWS VERSION IS V8.2,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 05 JULY 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:27:25 ON 23 AUG 2007

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 11:27:34 ON 23 AUG 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 AUG 2007 HIGHEST RN 945451-07-0

DICTIONARY FILE UPDATES: 22 AUG 2007 HIGHEST RN 945451-07-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10552493.str



ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14

chain bonds :

6-10

ring bonds :

1-5 1-2 2-3 3-4 4-5 4-6 5-9 6-7 7-8 8-9 10-11 10-14 11-12 12-13 13-14

exact/norm bonds :

1-5 1-2 6-10 10-11 10-14 11-12

exact bonds :

2-3 3-4 12-13 13-14

normalized bonds :

4-5 4-6 5-9 6-7 7-8 8-9

isolated ring systems :

containing 1 : 10 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom


11:Atom 12:Atom 13:Atom 14:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 11:27:51 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 21 TO ITERATE

100.0% PROCESSED 21 ITERATIONS

4 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

 BATCH **COMPLETE**

PROJECTED ITERATIONS: 146 TO 694

PROJECTED ANSWERS: .4 TO 200

L2 4 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 11:27:54 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 337 TO ITERATE

100.0% PROCESSED 337 ITERATIONS

86 ANSWERS

SEARCH TIME: 00.00.01

L3 86 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

. SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 11:27:59 ON 23 AUG 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Aug 2007 VOL 147 ISS 9
FILE LAST UPDATED: 22 Aug 2007 (20070822/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3 full
L4 5 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2006:1093832 CAPLUS

DOCUMENT NUMBER: 145:438607

TITLE: Process for preparing heterocyclylpyrrolopyridines and their use as antagonists of corticotropin-releasing factor (CRF) receptors.

INVENTOR(S): Andreotti, Daniele; Bacchi, Sergio; Delpogetto, Monica; Guelfi, Simone; Perboni, Alcide; Ribecai, Arianna; Spada, Simone; Stabile, Paolo; Tampieri, Marsia

PATENT ASSIGNEE(S): SB Pharmco Puerto Rico Inc, USA; Neurocrine Biosciences Inc

SOURCE: PCT Int. Appl., 42pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006108689	A2	20061019	WO 2006-EP3480	20060406
WO 2006108689	A3	20070201		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: GB 2005-7195 A 20050408

OTHER SOURCE(S): MARPAT 145:438607

GI




AB A process for preparation of title compds. [I; R = (substituted) aryl, heteroaryl; R1 = H, alkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, halo, amino, cyano; R2 = H, cycloalkyl, R9; R3 = cycloalkyl, R9; R9 = (substituted) alkyl; R2R3N = (substituted) 5-14 membered heterocycle] comprises treatment of (II; X = halo; R, R1 as above) with a Cu catalyst and a reactive derivative of the residue NR2R3. Thus, CuI and trans-N,N'-1,2-diaminocyclohexane were stirred together for 2-12 h in NMP; K2CO3, 2-(1H-pyrazol-3-yl)thiazole (preparation given), and 3-iodo-6-methyl-1-[2-methyl-4-(methoxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine (preparation given) in NMP were added followed by heating at 125° for 12-18 h to give 70% 6-methyl-1-[2-methyl-4-(methoxy)phenyl]-4-[3-(thiazol-2-yl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine.

IT 912848-66-9P
 RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heterocyclylpyrrolopyridines and their use as antagonists of corticotropin-releasing factor (CRF) receptors)

RN 912848-66-9 CAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



IT 491864-38-1P 491864-40-5P 491864-41-6P
 491864-42-7P 491864-46-1P 491865-57-7P
 491865-58-8P 491865-59-9P
 RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
 (preparation of heterocyclylpyrrolopyridines and their use as antagonists of corticotropin-releasing factor (CRF) receptors)


RN 491864-38-1 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 491864-40-5 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 491864-41-6 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 491864-42-7 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-6-methyl-1-[2-methyl-4-(trifluoromethoxy)phenyl]-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 491864-46-1 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 491865-57-7 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl-4-[3-(4-morpholinyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 491865-58-8 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl-4-[3-(2-pyridinyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 491865-59-9 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 4-[1,3'-bi-1H-pyrazol]-1'-yl-1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:1093785 CAPLUS
 DOCUMENT NUMBER: 145:438617
 TITLE: Process for preparation of heterocyclpyrrolopyridines from halopyrrolopyridines using copper catalysts.
 INVENTOR(S): Bacchi, Sergio; Delpogetto, Monica; Guelfi, Simone; Perboni, Alcide; Ribecai, Arianna; Stabile, Paolo; Tampieri, Marsia
 PATENT ASSIGNEE(S): SB Pharmco Puerto Rico Inc, USA; Neurocrine Biosciences Inc
 SOURCE: PCT Int. Appl., 37pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006108693	A2	20061019	WO 2006-EP3531	20060406
WO 2006108693	A3	20070705		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.:



GB 2005-7198

A 20050408

OTHER SOURCE(S):

MARPAT 145:438617

GI



AB Title compds. [I; R = (substituted) aryl, heteroaryl; R1 = H, cycloalkyl, alkyl, alkoxy, thioalkyl, alkenyl, alkynyl, haloalkyl, haloalkoxy, halo, amino, cyano; D = CR8R9, CR8; G = CR10R11, CR10; R8-R11 = H, cycloalkyl, alkyl, alkenyl, alkynyl, amino, cyano; dotted line = optional double bond; Z = (substituted) heterocyclyl; W = (substituted) carbocyclyl in which 1 C atom is replaced by CO, SOM, or 1-4 C atoms may be replaced by O, N, imino, CO, SOM, CO; m = 0-2], were prepared by treatment of (II; X = halo; R, R1 as above) with a reactive derivative of WZ (variables as above) catalyzed by Cu. Thus, CuI and trans-N,N'-dimethyl-1,2-diaminocyclohexane were stirred together in DMF for 2-12 h; K2CO3, 1-(1H-pyrazol-3-yl)-2-imidazolidinone (preparation given), and 3-bromo-6-methyl-1-[2-methyl-4-(methoxy)phenyl]-2,3-dihydropyrrolo[2,3-b]pyridine (preparation given) in DMF were added followed by heating at 125° for 36-42 h to give 70% 1-[1-[1-(4-methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]imidazolidin-2-one.


IT 491864-40-5P 491864-46-1P 786701-13-1P, 1-[1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]imidazolidin-2-one 786701-15-3P, 1-[1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-methylimidazolidin-2-one 786701-17-5P, 1-[1-[1-(2,4-Dichlorophenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]imidazolidin-2-one 786701-22-2P 786701-25-5P 786701-27-7P 786701-29-9P, 1-[1-[6-Methyl-1-[2-methyl-4-[(trifluoromethyl)oxy]phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]imidazolidin-2-one 786701-62-0P 786701-66-4P 786701-69-7P 786701-72-2P 786701-75-5P 786701-77-7P 786701-79-9P 786701-80-2P 786701-83-5P 912850-56-7P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation of heterocyclylpyrrolopyridines from halopyrrolopyridines using copper catalysts)


RN 491864-40-5 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 491864-46-1 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 786701-13-1 CAPLUS


CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 786701-15-3 CAPLUS


CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-methyl- (9CI) (CA INDEX NAME)

NAME)




RN 786701-17-5 CAPLUS

CN 2-Imidazolidinone, 1-[1-[1-(2,4-dichlorophenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-22-2 CAPLUS

CN 2-Imidazolidinone, 1-acetyl-3-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-25-5 CAPLUS

CN 2-Imidazolidinone, 1-[1-[1-(4-ethoxy-2-methylphenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-27-7 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-[2-methyl-4-(1-methylethoxy)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-29-9 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-[2-methyl-4-(trifluoromethoxy)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-62-0 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-66-4 CAPLUS

CN 2-Pyrrolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-69-7 CAPLUS

CN 2(1H)-Pyrimidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]tetrahydro- (9CI) (CA INDEX NAME)




RN 786701-72-2 CAPLUS

CN 2-Oxazolidinone, 3-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-75-5 CAPLUS

CN 1,2,5-Thiadiazolidine-2-carboxylic acid, 5-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-, methyl ester, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 786701-77-7 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 4-[3-(1,1-dioxido-1,2,5-thiadiazolidin-2-yl)-1H-pyrazol-1-yl]-2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 786701-79-9 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 4-[3-(1,1-dioxido-2-isothiazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl- (9CI)
(CA INDEX NAME)




RN 786701-80-2 CAPLUS

CN 2(1H)-Pyridinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 786701-83-5 CAPLUS

CN 2H-Imidazol-2-one, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 912850-56-7 CAPLUS

CN 3(2H)-Pyridazinone, 2-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]tetrahydro- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:927207 CAPLUS

DOCUMENT NUMBER: 141:395557

TITLE: Preparation of condensed heterocycles as CRF receptor antagonists for treatment of depression, anxiety, IBS, and IBD

INVENTOR(S): Andreotti, Daniele; Bernasconi, Giovanni; Castiglioni, Emiliano; Contini, Stefania; Di Fabio, Romano; Fazzolari, Elettra; Feriani, Aldo; Gentile, Gabriella; Mattioli, Mario; Mingardi, Anna; Sabbatini, Fabio; St.-Denis, Yves

PATENT ASSIGNEE(S): SB Pharmco Puerto Rico Inc., USA; Neurocrine Biosciences Inc.

SOURCE: PCT Int. Appl., 129 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094420	A1	20041104	WO 2004-IB1350	20040407
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004232551	A1	20041104	AU 2004-232551	20040407
CA 2521929	A1	20041104	CA 2004-2521929	20040407
EP 1611133	A1	20060104	EP 2004-726237	20040407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009117	A	20060328	BR 2004-9117	20040407
CN 1805958	A	20060719	CN 2004-80016189	20040407
JP 2006522799	T	20061005	JP 2006-506558	20040407
MX 2005PA10874	A	20060321	MX 2005-PA10874	20051010
NO 2005005238	A	20060109	NO 2005-5238	20051108
US 2007004708	A1	20070104	US 2006-552493	20060921



PRIORITY APPLN. INFO.:

GB 2003-8208
US 2003-485322P
WO 2004-IB1350

A 20030409
P 20030707
W 20040407

OTHER SOURCE(S):
GI

MARPAT 141:395557




AB Title [(pyrrolo[2,3-b]pyridinyl)pyrazolyl]imidazolidinones and related compds. I [wherein D = CR8R9, CR8; G = CR10R11, CR10; W = (un)substituted carbocyclyl, heterocyclyl; X = C, N; Y = N, CR7; Z = (un)substituted heterocyclyl, Ph; R = (un)substituted (hetero)aryl; R1 = H, (cyclo)alkyl, (halo)alkoxy, alkylthio, alkenyl, alkynyl, halo(alkyl), halo, NR3R4, CN; R3, R4 = independently H, alkyl; R7 = H, (halo)alkyl, halo; R8-R11 = independently H, (cyclo)alkyl, alkenyl, alkynyl, NR3R4, CN; and stereoisomers, prodrugs and pharmaceutically acceptable salts, or solvates thereof] were prepared as corticotropin-releasing factor (CRF) antagonists. For example, 4-iodo-6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine was coupled with 1-(1H-pyrazol-3-yl)imidazolidin-2-one (preparation of reactants given) in the presence of CuI, K2CO3, dodecane, and trans-cyclohexanediamine in anh. NMP to afford II (53%). In binding assays using recombinant human CRF1 and CRF2 receptors expressed in CHO cell membranes, compds. of the invention showed affinity for CRF receptors with Ki values of <10 μ M. Thus, I and their pharmaceutical compns. are useful for the treatment of depression, anxiety, IBS, and IBD (no data).

IT 786701-13-1P, 1-[1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]imidazolidin-2-one
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(CRF antagonist; preparation of [(pyrrolopyridinyl)pyrazolyl]imidazolidinone s and related compds. as CRF receptor antagonists for treatment of depression, anxiety, IBS, and IBD)

RN 786701-13-1 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



IT 786701-15-3P, 1-[1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-methylimidazolidin-2-one 786701-17-5P, 1-[1-[1-(2,4-Dichlorophenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]imidazolidin-2-one 786701-19-7P, 1-[1-[1-[2,4-Bis(trifluoromethyl)phenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-20-0P, 1-[1-[1-(4-Hydroxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-22-2P, 1-Acetyl-3-[1-[6-methyl-1-[2-methyl-4-(methoxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-25-5P, 1-[1-[1-[4-(Ethyloxy)-2-methylphenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-27-7P, 1-[1-[6-Methyl-1-[2-methyl-4-[(1-methylethyl)oxy]phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-29-9P, 1-[1-[6-Methyl-1-[2-methyl-4-[(trifluoromethyl)oxy]phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-31-3P, 3-Methyl-4-[6-methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]benzonitrile 786701-34-6P, 1-[1-[6-Methyl-1-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-35-7P, 4-[6-Methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)benzonitrile 786701-37-9P, 1-[1-[1-[2-(Difluoromethyl)-4-(methoxy)phenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-40-4P, 4-[6-Methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)oxybenzonitrile 786701-43-7P, 3-Ethyl-4-[6-methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]benzonitrile 786701-44-8P, 1-[1-[6-Methyl-1-[2-(methoxy)-4-(1H-pyrazol-1-yl)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-46-0P, 1-[1-[6-Methyl-1-(6-methyl-1,3-benzodioxol-5-yl)-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-49-3P, 1-[1-[6-Methyl-1-[2,4,6-tris(methoxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-57-3P, 1-[1-[2,6-Dimethyl-1-[2-methyl-4-(methoxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-62-0P, 1-[5-Methyl-1-[6-methyl-1-[2-methyl-4-(methoxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-64-2P, 1-[1-[1-[4-[(Difluoromethyl)oxy]-2-methylphenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786701-66-4P,


1-[1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]pyrrolidin-2-one 786701-69-7P,
 1-[1-[1-(4-Methoxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]tetrahydropyrimidin-2(1H)-one
 786701-72-2P, 3-[1-[6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-1,3-oxazolidin-2-one 786701-75-5P 786701-77-7P, 4-[3-(1,1-Dioxido-1,2,5-thiadiazolidin-2-yl)-1H-pyrazol-1-yl]-6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine 786701-79-9P, 4-[3-(1,1-Dioxido-2-isothiazolidinyl)-1H-pyrazol-1-yl]-6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridine 786701-80-2P, 3-Methyl-1-[1-[6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2(1H)-pyridinone 786701-81-3P, 2-[1-[6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3(2H)-pyridazinone 786701-83-5P, 1-[1-[6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-1,3-dihydro-2H-imidazol-2-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(CRF antagonist; preparation of [(pyrrolopyridinyl)pyrazolyl]imidazolidinone s and related compds. as CRF receptor antagonists for treatment of depression, anxiety, IBS, and IBD)


RN 786701-15-3 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 786701-17-5 CAPLUS

CN 2-Imidazolidinone, 1-[1-[1-(2,4-dichlorophenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-19-7 CAPLUS

CN 2-Imidazolidinone, 1-[1-[1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-20-0 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-(4-hydroxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-22-2 CAPLUS

CN 2-Imidazolidinone, 1-acetyl-3-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-25-5 CAPLUS

CN 2-Imidazolidinone, 1-[1-[1-(4-ethoxy-2-methylphenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-27-7 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-[2-methyl-4-(1-methylethoxy)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-29-9 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-[2-methyl-4-(trifluoromethoxy)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-(9CI) (CA INDEX NAME)




RN 786701-31-3 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 786701-34-6 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-(9CI) (CA INDEX NAME)




RN 786701-35-7 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)-(9CI) (CA INDEX NAME)




RN 786701-37-9 CAPLUS

CN 2-Imidazolidinone, 1-[1-[1-[2-(difluoromethyl)-4-methoxyphenyl]-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI)
(CA INDEX NAME)




RN 786701-40-4 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethoxy)- (9CI)
(CA INDEX NAME)




RN 786701-43-7 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-oxo-1-imidazolidinyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-ethyl- (9CI) (CA INDEX NAME)




RN 786701-44-8 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-46-0 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-(6-methyl-1,3-benzodioxol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-49-3 CAPLUS


CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-(2,4,6-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-57-3 CAPLUS
 CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-2,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 786701-62-0 CAPLUS
 CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-64-2 CAPLUS
 CN 2-Imidazolidinone, 1-[1-[1-[4-(difluoromethoxy)-2-methylphenyl]-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-66-4 CAPLUS

CN 2-Pyrrolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-69-7 CAPLUS

CN 2(1H)-Pyrimidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]tetrahydro- (9CI) (CA INDEX NAME)




RN 786701-72-2 CAPLUS

CN 2-Oxazolidinone, 3-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786701-75-5 CAPLUS

CN 1,2,5-Thiadiazolidine-2-carboxylic acid, 5-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-, methyl ester, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 786701-77-7 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 4-[3-(1,1-dioxido-1,2,5-thiadiazolidin-2-yl)-1H-pyrazol-1-yl]-2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 786701-79-9 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 4-[3-(1,1-dioxido-2-isothiazolidinyl)-1H-pyrazol-1-yl]-2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl- (9CI)
(CA INDEX NAME)




RN 786701-80-2 CAPLUS

CN 2(1H)-Pyridinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 786701-81-3 CAPLUS

CN 3(2H)-Pyridazinone, 2-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



RN 786701-83-5 CAPLUS

CN 2H-Imidazol-2-one, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-1,3-dihydro- (9CI) (CA INDEX NAME)




IT 786700-23-0P, N-[1-[6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]acetamide
 786700-24-1P, 1-[6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-amine
 786700-25-2P 786700-26-3P, 2-[[1-[6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]amino]ethanol 786700-27-4P, 3-[[1-[6-Methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]amino]-1-propanesulfonic acid 786700-28-5P, Phenyl
 [1-[6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]carbamate 786700-29-6P,
 1-(2,2-Diethoxyethyl)-3-[1-[6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]urea
 786700-34-3P, 1-Acetyl-3-[1-[1-(4-hydroxy-2-methylphenyl)-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786700-35-4P, 1-Acetyl-3-[1-[1-[4-(ethyloxy)-2-methylphenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786700-36-5P,
 1-Acetyl-3-[1-[6-methyl-1-[2-methyl-4-[(1-methylethyl)oxy]phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786700-37-6P, 1-(1-Methylethyl)-3-[1-[6-methyl-1-[2-methyl-4-[(1-methylethyl)oxy]phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786700-48-9P,
 1-[1-[6-Methyl-1-[2-methyl-4-[(trifluoromethyl)oxy]phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[[4-(methyloxy)phenyl]methyl]-2-imidazolidinone 786700-51-4P,
 3-Methyl-4-[6-methyl-4-[3-[3-[[4-(methyloxy)phenyl]methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]benzonitrile 786700-54-7P, 1-[1-[6-Methyl-1-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[[4-(methyloxy)phenyl]methyl]-2-imidazolidinone
 786700-57-0P, 4-[6-Methyl-4-[3-[3-[[4-(methyloxy)phenyl]methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)benzonitrile 786700-60-5P,
 1-[1-[1-[2-(Difluoromethyl)-4-(methyloxy)phenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[[4-(methyloxy)phenyl]methyl]-2-imidazolidinone 786700-64-9P,
 4-[6-Methyl-4-[3-[3-[[4-(methyloxy)phenyl]methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-[[trifluoromethyl]oxy]benzonitrile 786700-67-2P,
 3-Ethyl-4-[6-methyl-4-[3-[3-[[4-(methyloxy)phenyl]methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-1-yl]benzonitrile 786700-71-8P, 1-[1-[6-Methyl-1-[2-(methyloxy)-4-(1H-pyrazol-1-yl)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[[4-(methyloxy)phenyl]methyl]-2-imidazolidinone
 786700-74-1P, 1-[1-[6-Methyl-1-(6-methyl-1,3-benzodioxol-5-yl)-2,3-

dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[[4-(methyloxy)phenyl]methyl]-2-imidazolidinone 786700-77-4P,
 1-[[4-(Methyloxy)phenyl]methyl]-3-[1-[6-methyl-1-[2,4,6-tris(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone 786700-81-0P,
 1-[1-[1-[2,4-Bis(trifluoromethyl)phenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[[4-(methyloxy)phenyl]methyl]-2-imidazolidinone 786701-03-9P,
 1-[1-[2,6-Dimethyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[[4-(methyloxy)phenyl]methyl]-2-imidazolidinone 786701-09-5P,
 5-Methyl-1-[6-methyl-1-[2-methyl-4-(methyloxy)phenyl]-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-amine 786701-11-9P,
 1-Acetyl-3-[1-[1-[4-[(difluoromethyl)oxy]-2-methylphenyl]-6-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-2-imidazolidinone
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of [(pyrrolopyridinyl)pyrazolyl]imidazolidinones and related compds. as CRF receptor antagonists for treatment of depression, anxiety, IBS, and IBD)


RN 786700-23-0 CAPLUS

CN Acetamide, N-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786700-24-1 CAPLUS

CN 1H-Pyrazol-3-amine, 1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]- (9CI) (CA INDEX NAME)




RN 786700-25-2 CAPLUS

CN Glycine, N-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 786700-26-3 CAPLUS

CN Ethanol, 2-[[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]amino]- (9CI) (CA INDEX NAME)




RN 786700-27-4 CAPLUS

CN 1-Propanesulfonic acid, 3-[[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]amino]- (9CI) (CA INDEX NAME)




RN 786700-28-5 CAPLUS

CN Carbamic acid, [1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-, phenyl ester (9CI) (CA INDEX NAME)




RN 786700-29-6 CAPLUS

CN Urea, N-(2,2-diethoxyethyl)-N'-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-(9CI) (CA INDEX NAME)




RN 786700-34-3 CAPLUS

CN 2-Imidazolidinone, 1-acetyl-3-[1-[2,3-dihydro-1-(4-hydroxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-(9CI) (CA INDEX NAME)




RN 786700-35-4 CAPLUS

CN 2-Imidazolidinone, 1-acetyl-3-[1-[1-(4-ethoxy-2-methylphenyl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786700-36-5 CAPLUS

CN 2-Imidazolidinone, 1-acetyl-3-[1-[2,3-dihydro-6-methyl-1-[2-methyl-4-(1-methylethoxy)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)




RN 786700-37-6 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-[2-methyl-4-(1-methylethoxy)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 786700-48-9 CAPLUS
 CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-[2-methyl-4-(trifluoromethoxy)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

Me

RN 786700-51-4 CAPLUS
 CN Benzonitrile, 4-[2,3-dihydro-4-[3-[3-[(4-methoxyphenyl)methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A


Me

RN 786700-54-7 CAPLUS
CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 786700-57-0 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-4-[3-[3-[(4-methoxyphenyl)methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 786700-60-5 CAPLUS
CN 2-Imidazolidinone, 1-[1-[1-[2-(difluoromethyl)-4-methoxyphenyl]-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 786700-64-9 CAPLUS
CN Benzonitrile, 4-[2,3-dihydro-4-[3-[3-[(4-methoxyphenyl)methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 786700-67-2 CAPLUS
CN Benzonitrile, 4-[2,3-dihydro-4-[3-[3-[(4-methoxyphenyl)methyl]-2-oxo-1-imidazolidinyl]-1H-pyrazol-1-yl]-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-ethyl- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

Et


RN 786700-71-8 CAPLUS

CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A




RN 786700-74-1 CAPLUS
CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-(6-methyl-1,3-benzodioxol-5-yl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 786700-77-4 CAPLUS
 CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-6-methyl-1-(2,4,6-trimethoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 786700-81-0 CAPLUS
CN 2-Imidazolidinone, 1-[1-[1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 786701-03-9 CAPLUS
CN 2-Imidazolidinone, 1-[1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-2,6-dimethyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]-3-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



RN 786701-09-5 CAPLUS
 CN 1H-Pyrazol-3-amine, 1-[2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-5-methyl- (9CI) (CA INDEX NAME)



RN 786701-11-9 CAPLUS
 CN 2-Imidazolidinone, 1-acetyl-3-[1-[1-[4-(difluoromethoxy)-2-methylphenyl]]-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-4-yl]-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:610082 CAPLUS

DOCUMENT NUMBER: 141:157105

TITLE: Preparation of heteroaryl-substituted pyrrolo[2,3-b]pyridine derivatives as CRF receptor antagonists

INVENTOR(S): Castiglioni, Emiliano; Di Fabio, Romano; Feriani, Aldo; Micheli, Fabrizio; Sabbatini, Fabio; St-Denis, Yves

PATENT ASSIGNEE(S): SB Pharmco Puerto Rico Inc., USA; Neurocrine Biosciences Inc.; Glaxo Group Limited

SOURCE: PCT Int. Appl., 72 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004062665	A1	20040729	WO 2004-EP409	20040114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
EP 1583531	A1	20051012	EP 2004-701955	20040114
EP 1583531	B1	20070418		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006515334	T	20060525	JP 2006-500001	20040114
AT 359782	T	20070515	AT 2004-701955	20040114
US 2007066640	A1	20070322	US 2006-542196	20060303
PRIORITY APPLN. INFO.:			US 2003-440432P	P 20030116
			WO 2004-EP409	W 20040114

OTHER SOURCE(S): MARPAT 141:157105

GI



AB Pyrrolo[2,3-b]pyridines of formula I [R = aryl, heteroaryl; R1 = H, cycloalkyl, alkyl, alkoxy, CN, etc.; NR2R3 = (substituted) aromatic heterocycle; R4 = H, alkyl, halo, haloalkyl] are described, including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof, processes for their preparation, pharmaceutical compns. containing them

and their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF). Thus, II was prepared in several steps.


IT 727992-87-2P 727992-88-3P 727992-89-4P
 727992-90-7P 727992-91-8P 727992-92-9P
 727992-93-0P 727992-94-1P 727992-95-2P
 727992-96-3P 727992-97-4P 727992-98-5P
 727992-99-6P 727993-00-2P 727993-01-3P
 727993-02-4P 727993-03-5P 727993-04-6P
 727993-05-7P 727993-06-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of heteroaryl pyrrolopyridine derivs. as CRF receptor antagonists)

RN 727992-87-2 CAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-1-[6-methoxy-2-(trifluoromethyl)-3-pyridinyl]-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 727992-88-3 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-1-(6-methoxy-2-methyl-3-pyridinyl)-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 727992-89-4 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 1-(2,6-dimethoxy-3-pyridinyl)-2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 727992-90-7 CAPLUS
 CN 2-Pyridinamine, 5-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-N,N,4-trimethyl- (9CI) (CA INDEX NAME)




RN 727992-91-8 CAPLUS


CN 1H-Pyrrolo[2,3-b]pyridine, 1-[2-(difluoromethyl)-4-methoxyphenyl]-2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 727992-92-9 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 1-(2-chloro-4-methoxyphenyl)-2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 727992-93-0 CAPLUS
CN 1H-Pyrrolo[2,3-b]pyridine, 1-(2,4-dimethoxyphenyl)-2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 727992-94-1 CAPLUS

CN Benzonitrile, 3-chloro-4-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]- (9CI) (CA INDEX NAME)




RN 727992-95-2 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethoxy)- (9CI) (CA INDEX NAME)




RN 727992-96-3 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-ethyl- (9CI) (CA INDEX NAME)




RN 727992-97-4 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 1-(4-fluoro-2-methylphenyl)-2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 727992-98-5 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-6-methyl-1-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 727992-99-6 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-6-methyl-1-[4-nitro-2-(trifluoromethyl)phenyl]-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 727993-00-2 CAPLUS

CN Benzonitrile, 4-(4-[1,3'-bi-1H-pyrazol]-1'-yl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-methyl- (9CI) (CA INDEX NAME)




RN 727993-01-3 CAPLUS

CN Benzonitrile, 4-(4-[1,3'-bi-1H-pyrazol]-1'-yl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 727993-02-4 CAPLUS

CN Benzonitrile, 4-(4-[1,3'-bi-1H-pyrazol]-1'-yl)-2,3-dihydro-6-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl)-3-chloro- (9CI) (CA INDEX NAME)




RN 727993-03-5 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 4-[1,3'-bi-1H-pyrazol]-1'-yl-2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl- (9CI) (CA INDEX NAME)




RN 727993-04-6 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-pyridinyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 727993-05-7 CAPLUS

CN Benzonitrile, 3-chloro-4-[2,3-dihydro-6-methyl-4-[3-(2-pyridinyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]- (9CI) (CA INDEX NAME)



RN 727993-06-8 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-pyridinyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




IT 491865-06-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of heteroaryl pyrrolopyridine derivs. as CRF receptor antagonists)

RN 491865-06-6 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2003:76778 CAPLUS
 DOCUMENT NUMBER: 138:137173
 TITLE: Preparation of pyrazolyl- pyrrolo[2,3-b]pyridines and tetrahydro[1,8]naphthyridines as CRF receptor antagonists
 INVENTOR(S): Di Fabio, Romano; Micheli, Fabrizio; St-denis, Yves
 PATENT ASSIGNEE(S): Glaxo Group Limited, UK
 SOURCE: PCT Int. Appl., 35 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003008412	A2	20030130	WO 2002-EP7865	20020715
WO 2003008412	A3	20030501		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
GB 2378702	A	20030219	GB 2002-16041	20020711
CA 2451530	A1	20030130	CA 2002-2451530	20020715
AU 2002328899	A1	20030303	AU 2002-328899	20020715
EP 1425280	A2	20040609	EP 2002-764696	20020715
EP 1425280	B1	20060830		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002011171	A	20040810	BR 2002-11171	20020715
CN 1525972	A	20040901	CN 2002-813866	20020715
HU 200400465	A2	20050128	HU 2004-465	20020715
JP 2005514328	T	20050519	JP 2003-513971	20020715
NZ 530043	A	20060331	NZ 2002-530043	20020715
EP 1695974	A1	20060830	EP 2006-76176	20020715
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
AT 338042	T	20060915	AT 2002-764696	20020715
ES 2271327	T3	20070416	ES 2002-2764696	20020715
IN 2003DN02137	A	20070302	IN 2003-DN2137	20031209
ZA 2003009708	A	20050121	ZA 2003-9708	20031215

US 2004171607	A1	20040902	US 2004-483792	20040114
US 7253284	B2	20070807		
NO 2004000206	A	20040316	NO 2004-206	20040116
MX 2004PA00494	A	20040504	MX 2004-PA494	20040116
HK 1066535	A1	20070309	HK 2004-109443	20041130
PRIORITY APPLN. INFO.:			GB 2001-17396	A 20010717
			EP 2002-764696	A3 20020715
			WO 2002-EP7865	W 20020715
OTHER SOURCE(S):	MARPAT 138:137173			
GI				


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Pyrazolyl- pyrrolo[2,3-b]pyridines and tetrahydro[1,8]naphthyridines [I; wherein R = (substituted) aryl, heteroaryl; R1 = H, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, halo(C1-C6)alkyl, halo(C1-C6)alkoxy, halogen, amino, or cyano; R2 = H, (C3-C7)cycloalkyl; R3 = (C3-C7)cycloalkyl; or R2 and R3 together with N form a (substituted) 5-14 membered heterocycle; R4 = H, (C1-C6)alkyl, halo, halo(C1-C6)alkyl; X = C, N; n = 1 or 2] were prepared For example, compound (II) was prepared by the provided method. The prepared compds. are useful in the treatment of conditions mediated by corticotropin-releasing factor (CRF) (no data).

IT 491864-38-1P 491864-40-5P 491864-41-6P
491864-42-7P 491864-46-1P 491865-57-7P
491865-58-8P 491865-59-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolyl- pyrrolo[2,3-b]pyridines and tetrahydro[1,8]naphthyridines as CRF receptor antagonists)


RN 491864-38-1 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 491864-40-5 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-methyl- (9CI) (CA INDEX NAME)




RN 491864-41-6 CAPLUS

CN Benzonitrile, 4-[2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]-1H-pyrrolo[2,3-b]pyridin-1-yl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 491864-42-7 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-6-methyl-1-[2-methyl-4-(trifluoromethoxy)phenyl]-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 491864-46-1 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-1-(4-methoxy-2-methylphenyl)-6-methyl-4-[3-(2-thiazolyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 491865-57-7 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl-4-[3-(4-morpholinyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 491865-58-8 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl-4-[3-(2-pyridinyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)




RN 491865-59-9 CAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine, 4-[1,3'-bi-1H-pyrazol]-1'-yl-1-[2,4-bis(trifluoromethyl)phenyl]-2,3-dihydro-6-methyl- (9CI) (CA INDEX NAME)



IT 491865-06-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of pyrazolyl- pyrrolo[2,3-b]pyridines and
 tetrahydro[1,8]naphthyridines as CRF receptor antagonists)
 RN 491865-06-6 CAPLUS
 CN 1H-Pyrrolo[2,3-b]pyridine, 2,3-dihydro-6-methyl-4-[3-(2-thiazolyl)-1H-
 pyrazol-1-yl]- (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 11:27:25 ON 23 AUG 2007)

FILE 'REGISTRY' ENTERED AT 11:27:34 ON 23 AUG 2007

L1 STRUCTURE UPLOADED

L2 4 S L1

L3 86 S L1 FULL

FILE 'CAPLUS' ENTERED AT 11:27:59 ON 23 AUG 2007

L4 5 S L3 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

26.82

199.13

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

CA SUBSCRIBER PRICE

ENTRY	SESSION
-3.90	-3.90

STN INTERNATIONAL LOGOFF AT 11:28:41 ON 23 AUG 2007